Very low expression of PD-L1 in medullary thyroid carcinoma

Comprehensive screening for PD-L1 expression in thyroid cancer

(2017) Soomin Ahn et al.   ENDOCRINE-RELATED CANCER

Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence

(2017) Rong-liang Shi et al.   THYROID

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1

(2017) Patricia Gaule et al.   JAMA Oncology

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer

(2016) Jill J. Bastman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets

(2015) Hao Wu et al.   PATHOLOGY & ONCOLOGY RESEARCH

BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration

(2014) Trevor E. Angell et al.   THYROID

Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation

(2012) Lucas Leite Cunha et al.   ENDOCRINE-RELATED CANCER

Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations inRETandRAS

(2012) Nishant Agrawal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM